Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503611 | 1.00 | CD274 (0.34) | CD274PDCD1LG2POLBTDP1PDCD1 | |
| SCHEMBL26631490 | 0.87 | GPR119 (0.42) | CNR2 | |
| SCHEMBL29427128 | 0.87 | GPR119 (0.42) | CNR2 | |
| SCHEMBL30503541 | 0.86 | DGAT1 (0.37) | CD274PDCD1LG2POLBTDP1HCRTR1 | |
| SCHEMBL26631319 | 0.86 | DGAT1 (0.37) | CD274PDCD1LG2POLBTDP1HCRTR1 | |
| SCHEMBL29426872 | 0.85 | CHRM4 (0.40) | CD274PDCD1LG2PDCD1CNR2CHRM4 | |
| SCHEMBL26631093 | 0.85 | CHRM4 (0.40) | CD274PDCD1LG2PDCD1CNR2CHRM4 | |
| SCHEMBL26739514 | 0.85 | CHRM4 (0.40) | CD274PDCD1LG2PDCD1CNR2CHRM4 | |
| SCHEMBL26750579 | 0.83 | CNR2 (0.32) | CD274PDCD1LG2PDCD1CNR2CHRM4 | |
| SCHEMBL25413318 | 0.83 | DGAT1 (0.35) | CD274PDCD1LG2POLBTDP1PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CD274 3603/4885PDCD1LG2 2887/4885POLB 846/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CD274 3625/4885PDCD1LG2 2901/4885POLB 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.